Physician profile
Samir Patel
NPI 1427519552
$1,319.86
in general payments reported to CMS, 2019-2025
16 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $151 · 2023: $357 · 2024: $198 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $235.91 | 2023 | Lupkynis |
| Akebia Therapeutics INC | $169.73 | 2025 | Vafseo |
| Astrazeneca Pharmaceuticals LP | $130.68 | 2023-2025 | Lokelma, Farxiga |
| Sanofi-Aventis U.S. LLC | $121.82 | 2025 | |
| Alexion Pharmaceuticals, INC. | $120.40 | 2022 | |
| Amgen INC. | $109.44 | 2025 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.26 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $57.35 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $55.55 | 2022-2024 | Velphoro |
| Ardelyx, INC. | $47.27 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $44.67 | 2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $44.03 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.29 | 2024 | Jynarque |
| Calliditas Therapeutics US INC. | $28.06 | 2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $27.00 | 2023 | Jynarque |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $19.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.